<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04664361</url>
  </required_header>
  <id_info>
    <org_study_id>C1598</org_study_id>
    <nct_id>NCT04664361</nct_id>
  </id_info>
  <brief_title>Effect of NMN on Muscle Recovery and Physical Capacity in Healthy Volunteers With Moderate Physical Activity</brief_title>
  <official_title>Randomized, Double-blind, Placebo-controlled Clinical Trial of Nicotinamide Mononucleotide on Muscle Recovery and Physical Capacity in Healthy Volunteers With Moderate Physical Activity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seneque SA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>CEN Nutriment</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre d'Expertise de la Performance</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>LGD</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Seneque SA</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effect of NMN supplementation (250 and 500&#xD;
      mg/day over 38 days) compared to placebo in healthy volunteers with moderate physical&#xD;
      activity on muscle recovery, physical capacity, cardiorespiratory recovery, the perception of&#xD;
      the arduousness of the effort, the variation in blood lactate levels before and after&#xD;
      physical exercise, the perception of the intensity of post-exercise muscle pain (cramps), the&#xD;
      body composition and Nicotinamide-Adenine Mononucleotide (NAD+) level in blood.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 9, 2021</start_date>
  <completion_date type="Anticipated">September 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized double-blind, placebo-controlled clinical trial conducted on 3 parallel groups</intervention_model_description>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evolution of muscle recovery</measure>
    <time_frame>before and after 21 and 38 days of treatment</time_frame>
    <description>Wingate Anaerobic Test (WANT) preformed post-endurance test (at 85% maximum aerobic speed)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in physical capacity</measure>
    <time_frame>before and after 21 and 38 days of treatment</time_frame>
    <description>physical capacity evaluated during an endurance test (at 85% maximum aerobic speed) by the maximum duration (time limit)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in cardiorespiratory recovery</measure>
    <time_frame>before and after 21 and 38 days of treatment</time_frame>
    <description>Measurement of blood pressure and heart rate at rest and at intervals of several minutes after the endurance test (at 85% maximum aerobic speed)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in the perception of the arduousness of the effort</measure>
    <time_frame>before and after 21 and 38 days of treatment</time_frame>
    <description>evaluated by the Borg scale during the endurance test (at 85% maximum aerobic speed)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in blood lactate levels before and after physical exercise</measure>
    <time_frame>before and after 21 and 38 days of treatment</time_frame>
    <description>blood lactate levels before and after the endurance test (at 85% maximum aerobic speed)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in the perception of the intensity of post-exercise muscle pain (cramps)</measure>
    <time_frame>before and after 21 and 38 days of treatment</time_frame>
    <description>post-exercise muscular pain in evaluated using a 7 points numerical scale, 24, 48 and 72 hours after the endurance test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in the body composition</measure>
    <time_frame>before and after 21 and 38 days of treatment</time_frame>
    <description>fat mass, muscle mass, visceral fat, water mass determined by Bioelectrical Impedance Analysis (BIA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes blood NAD+ levels</measure>
    <time_frame>before and after 21 and 38 days of treatment</time_frame>
    <description>Evaluation of cellular NAD+ concentration in blood from baseline to the end of study</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Physical Activity</condition>
  <condition>Muscle Recovery</condition>
  <arm_group>
    <arm_group_label>NMN 250</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NMN tablet (250 mg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NMN 500</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NMN tablet (500 mg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>NMN-free placebo tablet.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Nicotinamide mononucleotide</intervention_name>
    <description>Daily supplementation with NMN at 250 and 500 mg for 38 days in total</description>
    <arm_group_label>NMN 250</arm_group_label>
    <arm_group_label>NMN 500</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Daily supplementation with placebo for 38 days in total</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Body Mass Index ranging from 20 to 28 kg/m2(bounds included);&#xD;
&#xD;
          -  Body weight between of 70 kg to 100 kg (including limits);&#xD;
&#xD;
          -  Able to provide written informed consent to participate;&#xD;
&#xD;
          -  Having a moderate level of physical activity according to the Global Physical Activity&#xD;
             Questionnaire (GPAQ);&#xD;
&#xD;
          -  Having a sport practice involving endurance or split races (including collective or&#xD;
             individual sports) or cycling.&#xD;
&#xD;
          -  Agreeing not to change their physical activity habits throughout the study;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Having a mental state that does not allow them to give free and informed consent to&#xD;
             participate in the study;&#xD;
&#xD;
          -  Being taking regularly or have taken within the last month any medication or dietary&#xD;
             supplement that may increase endurance, recovery, or physical capacity. In particular,&#xD;
             the following drugs are strictly prohibited: beta-2 agonists such as salbutamol&#xD;
             (Ventolin®), terbutaline (Bricanyl®), fenoterol (Berotec®), salmeterol (Serevent®) and&#xD;
             formoterol (Foradil®) as well as corticosteroids;&#xD;
&#xD;
          -  Having history of a recent (less than 3 months) lower extremity muscle injury;&#xD;
&#xD;
          -  Presenting a depressive syndrome;&#xD;
&#xD;
          -  Presenting, in the opinion of the investigator, any symptomatology, pathology or&#xD;
             cardiovascular risk factors that are incompatible with the conduct of the study or&#xD;
             with the performance of a stress test or that could influence the results of the&#xD;
             study, and in particular: 1) an abnormal resting and/or stress ECG at the inclusion&#xD;
             visit according to the investigator; 2) presence of abnormalities in the lipid balance&#xD;
             (Total Cholesterol, Triglycerides, HDL, LDL), blood glucose, and/or hemodynamic&#xD;
             parameters;&#xD;
&#xD;
          -  Presenting an abnormal biological balance (Creatinine, Uric acid, Troponin, Alanine&#xD;
             aminotransferase / Aspartate aminotransferase, Lactate dehydrogenase, Creatine Kinase,&#xD;
             C-reactive protein, Transferrin, Bilirubin, Gamma Glutamyl transpeptidase, Cholesterol&#xD;
             (EAL), Glycemia, Ionogram, Alkaline phosphatase );&#xD;
&#xD;
          -  Being not be compliant with the constraints imposed by the protocol;&#xD;
&#xD;
          -  Having an allergy or a contraindication to the components of the studied products;&#xD;
&#xD;
          -  Being already involved in another clinical trial or being in the exclusion period of a&#xD;
             previous clinical trial;&#xD;
&#xD;
          -  Being unable to understand, speak and read French fluently;&#xD;
&#xD;
          -  Being not affiliated with a health insurance company;&#xD;
&#xD;
          -  Being vulnerable persons or persons deprived of liberty by a judicial or&#xD;
             administrative decision;&#xD;
&#xD;
          -  Consuming illegal psychotropic substances or having an alcohol consumption of more&#xD;
             than 2 glasses of alcohol/wine per day.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>49 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nadège PLAZA, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CEN Nutriment</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Florent Herpin</last_name>
    <phone>+33 3 80 68 05 06</phone>
    <email>florent.herpin@groupecen.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Laurent Laganier, PharmD</last_name>
    <phone>+33 7 50 96 41 12</phone>
    <email>laurent.laganier@lgdfrance.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CEN Nutriment</name>
      <address>
        <city>Dijon</city>
        <zip>21000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Florent Herpin</last_name>
      <phone>03 80 68 05 06</phone>
      <email>florent.herpin@groupecen.com</email>
    </contact>
    <investigator>
      <last_name>Nadege Plaza, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>December 10, 2020</study_first_submitted>
  <study_first_submitted_qc>December 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 11, 2020</study_first_posted>
  <last_update_submitted>March 22, 2021</last_update_submitted>
  <last_update_submitted_qc>March 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Nicotinamide mononucleotide</keyword>
  <keyword>Muscle pain</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Niacinamide</mesh_term>
    <mesh_term>Niacin</mesh_term>
    <mesh_term>Nicotinic Acids</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

